Gene therapy: theoretical and bioethical concepts (Q35212648)

7 August 2017

1 reference

title

Gene therapy: theoretical and bioethical concepts (English)

1 reference

7 August 2017

0 references

0 references

Kevin R Smith

1

1 reference

7 August 2017

language of work or name

1 reference

1 July 2003

1 reference

Archives of Medical Research

7 August 2017

published in

1 reference

7 August 2017

volume

34

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

247-268

1 reference

Animal genetic manipulation--a utilitarian response.

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

1 reference

7 January 2021

Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Silencing of gene expression: implications for design of retrovirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Retrovirus vector silencing is de novo methylase independent and marked by a repressive histone code

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Mechanisms that regulate silencing of gene expression from retroviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Amplified and tissue-directed expression of retroviral vectors using ping-pong techniques.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Retroviral vectors. From laboratory tools to molecular medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Replicative retroviral vectors for cancer gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene targeting with retroviral vectors: recombination by gene conversion into regions of nonhomology

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Safety considerations in somatic gene therapy of human disease with retrovirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Safety Issues Related to Retroviral-Mediated Gene Transfer in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

The safety of retroviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy for SCID--a complication after remarkable progress

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy. Seeking the cause of induced leukemias in X-SCID trial

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Widespread long-term gene transfer to mouse skeletal muscles and heart

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Intravascular adenoviral agents in cancer patients: lessons from clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Points to consider for ethics committees in human gene therapy trials

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy: trials and tribulations

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Adenovirus and adeno-associated virus vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Adeno-associated virus vectors for gene therapy: more pros than cons?

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Experimental transmission of human hepatitis delta virus to the laboratory mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Multiple applications for replication-defective herpes simplex virus vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

The use of herpes simplex virus-based vectors for gene delivery to the nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Liposomes as carriers for in vivo gene transfer and expression

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Improvements in cationic liposomes for in vivo gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

pH-sensitive liposomes: acid-induced liposome fusion

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Paramyxovirus fusion: a hypothesis for changes

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Safety evaluation of hemagglutinating virus of Japan--artificial viral envelope liposomes in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

The effects of jet nebulisation on cationic liposome-mediated gene transfer in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Aerosol and intravenous transfection of human alpha 1-antitrypsin gene to lungs of rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Mechanisms and kinetics of liposome-cell interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Liposomes as gene carriers: efficient transformation of mouse L cells by thymidine kinase gene

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Poxviruses as expression vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Development of echogenic, plasmid-incorporated, tissue-targeted cationic liposomes that can be used for directed gene delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene transfer in higher animals: theoretical considerations and key concepts

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene transfer by electroporation

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene correction in hematopoietic progenitor cells by homologous recombination

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Sparking new frontiers: using in vivo electroporation for genetic manipulations

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Progress and prospects: naked DNA gene transfer and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Transformation of microbes, plants and animals by particle bombardment

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Successful biolistic transformation of mouse pancreatic islets while preserving cellular function

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

DNA cancer vaccines: a gene gun approach

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Theoretical mechanisms in targeted and random integration of transgene DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

The emerging fields of suicide gene therapy and virotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Metabolic suicide genes in gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Progress in antisense oligonucleotide therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy in infants with severe combined immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy of severe combined immunodeficiencies

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Treatment of adenosine deaminase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Adeno-associated virus-mediated gene transfer for hemophilia B.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Cystic fibrosis clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy progress and prospects: cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy for cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy for inherited lung disorders: an insight into pulmonary defence

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

1 reference

7 January 2021

Gene therapy of muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy progress and prospects: alpha-1 antitrypsin

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy and retinitis pigmentosa: advances and future challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Correction of sickle cell disease in transgenic mouse models by gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

On the scientific and ethical issues of fetal somatic gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Genetic therapies for the fetus

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Restenosis and gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy for restenosis: current status

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Clinical trials of gene therapy for atherosclerotic cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

The ependymal route to the CNS: an emerging gene-therapy approach for MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy for diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene transfer to the brain: emerging therapeutic strategy in psychiatry?

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Progress and limitations in cancer gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Cancer gene therapy: fringe or cutting edge?

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Cancer gene therapy: scientific basis.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Ex vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defence in the B16 melanoma model

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Oncolytic viruses as therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Oncolytic adenoviruses for treatment of brain tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Adenoviruses in oncology: a viable option?

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

The potential therapeutic gain of radiation-associated gene therapy with the suicide gene cytosine deaminase

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Potential benefits of combining cytosine deaminase/5-fluorocytosine gene therapy and irradiation for prostate cancer: experimental study

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Antisense therapy: current status in prostate cancer and other malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Antisense therapy for cancer--the time of truth

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Current status of ribozymes as gene therapy agents for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Ribozymes. Their design and use in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Triplex-directed modification of genes and gene activity

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

RNA interference may be more potent than antisense RNA in human cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Tumor suppressor gene therapy for cancer: from the bench to the clinic.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy for head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy for bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

The potential of gene therapy in the treatment of pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Genetic protection of repopulating hematopoietic cells with an improved MDR1-retrovirus allows administration of intensified chemotherapy following stem cell transplantation in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Improved post-transcriptional processing of an MDR1 retrovirus elevates expression of multidrug resistance in primary human hematopoietic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

MDR1 gene expression in NOD/SCID repopulating cells after retroviral gene transfer under clinically relevant conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Cancer immunogene therapy: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Cancer vaccines: dream, reality, or nightmare?

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy for infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy of HIV-1 infection using lentiviral vectors expressing anti-HIV-1 genes

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

The potential for gene therapy in the treatment of autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Vectors for the treatment of autoimmune disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene therapy for central nervous system injury: the use of cationic liposomes: an invited review

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Development of gene-based therapies for cartilage repair

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Prospects for gene therapy in pediatric neurosurgery

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

In utero gene therapy: transfer and long-term expression of the bacterial neo(r) gene in sheep after direct injection of retroviral vectors into preimmune fetuses

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Absence of germline infection in male mice following intraventricular injection of adenovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Successful expression of beta-galactosidase and factor IX transgenes in fetal and neonatal sheep after ultrasound-guided percutaneous adenovirus vector administration into the umbilical vein

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Human gene therapy: scientific and ethical considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

1 reference

7 January 2021

Review: molecular biology of transgenic animals.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

The majority of G0 transgenic mice are derived from mosaic embryos

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Targeted correction of a major histocompatibility class II E alpha gene by DNA microinjected into mouse eggs

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Specific Ablation of Thyroid Follicle Cells in Adult Transgenic Mice*

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Expression of human blood clotting factor VIII in the mammary gland of transgenic sheep

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Genetic transformation of mouse embryos by microinjection of purified DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Embryonic stem cells, creating transgenic animals

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Engineering the mouse genome by site-specific recombination

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Ten years of gene targeting: targeted mouse mutants, from vector design to phenotype analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Sheep cloned by nuclear transfer from a cultured cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Transgenic technology in farm animals--progress and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Gene targeting in livestock: a preview

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Production of gene-targeted sheep by nuclear transfer from cultured somatic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Nuclear transfer technologies: between successes and doubts

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Nuclear cloning and epigenetic reprogramming of the genome

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Mouse cloning with nucleus donor cells of different age and type.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Sperm cell mediated transgenesis: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Foreign DNA introduced into the vas deferens is gained by mammalian spermatozoa

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Generation of genetically modified mice by spermatozoa transfection in vivo: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

Human germline gene therapy reconsidered

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2803%2900070-5

7 January 2021

10.1016/S0188-4409(03)00070-5

Identifiers

DOI

1 reference

7 August 2017

1 reference